within Pharmacolibrary.Drugs.ATC.J;

model J04AB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0001,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0011666666666666668,
    Tlag           = 900
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rifamycin is an antibiotic belonging to the rifamycin group, used primarily for the treatment of tuberculosis and other bacterial infections caused by susceptible strains. It exerts its antibacterial action by inhibiting DNA-dependent RNA polymerase in susceptible organisms. Rifamycin preparations are approved and used clinically, with formulations for oral, intravenous, or local (e.g., intestinal) administration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after a single oral dose of rifamycin SV in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Niemi, M, et al., &amp; Kivistö, KT (2003). Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical pharmacokinetics</i> 42(9) 819–850. DOI:<a href=\"https://doi.org/10.2165/00003088-200342090-00003\">10.2165/00003088-200342090-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12882588/\">https://pubmed.ncbi.nlm.nih.gov/12882588</a></p></li><li><p>Abulfathi, AA, et al., &amp; Reuter, H (2019). Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. <i>Clinical pharmacokinetics</i> 58(9) 1103–1129. DOI:<a href=\"https://doi.org/10.1007/s40262-019-00764-2\">10.1007/s40262-019-00764-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31049868/\">https://pubmed.ncbi.nlm.nih.gov/31049868</a></p></li><li><p>Bock, M, et al., &amp; Moser, C (2023). Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 77(2) 242–251. DOI:<a href=\"https://doi.org/10.1093/cid/ciad168\">10.1093/cid/ciad168</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36947131/\">https://pubmed.ncbi.nlm.nih.gov/36947131</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AB03;
